Summary:
Graft rejection in patients with severe aplastic anemia (SAA) following allogeneic hematopoietic stem cell transplantation (HSCT) is strongly associated with a large number of prior transfusions and with prolonged disease duration before transplant. We retrospectively analyzed the outcomes and the factor affecting these multitransfused SAA patients, who had received triple agent immunosuppression and high doses of stem cells to overcome rejection. In total, 113 patients with SAA who had a median 16 months (range 1–216) of disease duration were transplanted using HLA-matched sibling donors after conditioning with cyclophosphamide (CY), procarbazine (PCB), and ATG. Graft failure occurred in 16 of the eligible 113 patients, and with a median follow-up of 30 months (range, 1–80), probability of overall rejection was 15%. Specifically, the multitransfused patients who received high doses of stem cells with T-cell depletion showed the lowest rejection rate, 5.6%, compared with 30.3% in multitransfused patients with bone marrow stem cells alone (P=0.0310). Disease duration (P=0.0338) and the number of infused CD34+cells (P=0.0101) were associated with a high risk of graft rejection on multivariate analysis. ABO mismatch and the number of CD34+ cells were significant factors in the incidence of acute graft-versus-host-disease (GVHD). The incidence of chronic GVHD among patients with sustained engraftment was 13/109 (11.9%). With the same follow-up period, probability of disease-free survival for the entire group of patients at 6 years was 89% and the only factor associated with long-term survival was rejection (P=0.0241). These results suggest that allogeneic HSCT conditioned with triple agent immunosuppression, and specifically with high-dose stem cell return is probably an effective treatment for successful engraftment in SAA patients with a high risk of rejection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Camitta BM, Thomas ED, Nathan DG et al. A Prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504–514.
Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anemia by antithymocyte globulin with and with- out allogeneic bone-marrow infusions. Lancet 1977; iv: 1145–1148.
Bacigalupo A, Broccia G, Corda G et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. Blood 1995; 85: 1348–1353.
Thomas ED, Storb R, Giblett ER et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol 1976; 4: 97–102.
Wright SE, Thomas ED, Buckner CD et al. Experience with second marrow transplants. Exp Hematol 1976; 4: 221–226.
Meuwissen HJ, Moore EC, Strauss HS et al. Successful retransplantation of bone marrow following failure of initial engraftment in a patient with aplastic anemia. J Pediatr 1976; 89: 588–592.
Storb R, Thomas ED, Weiden PL et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood 1976; 48: 817–841.
Gluckman E, Horowitz MM, Champlin RE et al. Bone Marrow Transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269–275.
Arranz R, Otero MJ, Ramos R et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplant 1994; 13: 383–387.
Deeg HJ, Leisenring W, Storb R et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637–3645.
Bacigalupo A, Oneto R, Bruno B et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for blood and marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 2000; 103: 19–25.
Ball SE. The modern management of severe aplastic anaemia. Br J Haematol 2000; 110: 41–53.
Passweg JR, Socie G, Hinterberger W et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?. Blood 1997; 90: 858–864.
Storb R, Blume KG, O'Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001; 7: 39–44.
Weiden PL, Storb R, Thomas ED et al. Preceding transfusions and marrow graft rejection in dogs and man. Transplant Proc 1976; 8: 551–554.
Bacigalupo A. Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Working Party on Severe Aplastic Anaemia of the European blood and marrow transplantation Group. Eur J Haematol 1996; 60 (Suppl.): 16–19.
May WS, Sensenbrenner LL, Burns WH et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant 1993; 11: 459–464.
Young NS, Maciejewsi J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372.
Young NS. Autoimmunity and its treatment in aplastic anemia. Ann Intern Med 1997; 126: 166–168.
Herrera-Garza J, Jaime-Perez J, Montermayor J et al. High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant 1999; 24: 845–848.
Naparstek E, Delukina M, Or R et al. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp Hematol 1999; 27: 1210–1218.
Dufour C, Dallorso S, Casarino L et al. Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant. 1999; 23: 743–745.
Thomas ED, Storb R, Giblett ER et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol 1976; 4: 97–102.
Parkman R, Rappeport J, Camitta B et al. Successful use of multiagent immunosuppression in the bone marrow transplantation of sensitized patients. Blood 1978; 52: 1163–1169 .
Gluckman E, Horowitz MM, Champlin RE et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269–275.
Min CK, Kim DW, Lee JW et al. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematol 2000; 104: 185–192.
Min CK, Kim DW, Lee JW et al. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica 2001; 86: 303–310.
Min CK, Kim DW, Lee JW et al. Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. Am J Hematol 2002; 69: 15–22.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, H., Park, C., Park, Y. et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant 31, 79–86 (2003). https://doi.org/10.1038/sj.bmt.1703786
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703786
Keywords
This article is cited by
-
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
Journal of Hematology & Oncology (2017)
-
Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia
Bone Marrow Transplantation (2016)
-
HLA-matched sibling transplantation with BM and CD34+-purified PBSCs in adult patients with high-risk severe aplastic anemia to overcome graft rejection without an increase in GVHD
Bone Marrow Transplantation (2010)
-
Feasibility of NIH consensus criteria for chronic graft-versus-host disease
Leukemia (2009)
-
Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2008)